Health (Amendment) Act And Related Laws

Original Language Title: změna zákona o VZP ČR a souvisejících zákonů

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$20 per month, or Get a Day Pass for only USD$4.99.
438/2004 Sb.



LAW



of 24 July 2003. June 2004,



amending Act No. 553/1991 Coll. on General health insurance company

The Czech Republic, as subsequently amended, Act No. 280/1992 Coll., on the

departmental, industry, corporate, and other health insurance companies,

as amended, Act No. 592/1992 Coll., on

universal health insurance, as subsequently amended, and Act No.

48/1997 Coll., on public health insurance and amending and supplementing

some related laws, as amended



Change: 117/2006 Sb.



Parliament has passed the following Act of the United States:



PART THE FIRST



Amendment of the Act on general health insurance company in the Czech Republic



Article. (I)



Act No. 551/1991 Coll., on the Czech General health insurance company

Republic, as amended by Act No. 586/1992 Coll., Act No. 10/1993 Coll.

Act No. 60/1995 Coll., Act No. 145/1996 Coll., Act No. 48/1997 Coll.,

Act No. 305/1997 Coll., Act No. 93/1998 Coll., Act No. 125/1998 Coll.,

Act No. 69/2000 Coll., Act No. 132/2000 Coll., Act No. 220/2000 Coll.

Act No. 48/2002 Coll., Act No. 422/2003 Coll. and Act No. 461/2003 Coll.,

is amended as follows:



1. In paragraph 6 of section 7 including the footnotes # 3a) and 3b):



"(7) the proceeds from the fines, the price increases to premiums and penalties to be imposed in accordance with

the specific legislation governing the public health

insurance ^ 3a) and received by the Insurer during a calendar year may

Insurance undertaking to allocate to the Fund; These allocations to fund prevention

can be used during a calendar year to perform as a deposit, so that their

the total amount for the calendar year does not exceed 0.3% of the total

income premiums after reallocation of carried out according to the law of insurance

for general health insurance. ^ 3b)



3A) Act No. 586/1992 Coll., on premiums for general health

insurance, as amended.



Act No. 48/1997 Coll., on public health insurance and amending and

certain related laws, as amended.



3B) Act No. 586/1992 Coll., as amended. ".



2. In article 7 (2). 1, letter a) is added:



"and the underlying fund); the source of the underlying fund are insurance payments to the

health insurance premiums and other receipts to the extent

an implementing regulation. Basic health insurance fund

is used to cover health care paid for by public health

insurance, allocations to the operational fund to cover the cost of the action

Insurance companies, to other funds and the allocations to other payments in the range of

provided for an implementing regulation, ".



3. In article 7 (2). 1 (b). (b)) the first sentence, the words "Reserve Fund. Minimum

the amount of the reserve fund is 3% "shall be replaced by the words" Reserve Fund; the amount of the

the reserve fund amounts to 1.5% ".



4. In article 7 (2). 1 letters e) and (f)):



"e) Fund assets



(f) the reproduction of the pool assets.) ".



5. In article 7 (2). 2 (b)), including footnotes, no. 9):



"(b)) the Fund prevention; from the pool you can pay health care prevention beyond the

health care, which is paid for by public health insurance

According to a special legal regulation, ^ 9) with a proven preventive,

diagnostic or therapeutic effect, if provided to the insureds in the

connection with their existing or impending disease. Resources

Prevention Fund can also be used to implement preventive health care

programs used for the detection of serious illness, support

rehabilitation recovery activities leading to a demonstrable improvement

the State of health of the participants and to support projects that support

increase the quality of health care, the healthy way of life and health

policy holders. The source of the Fund are funds from a share

management of after tax laid down by the governing bodies of an insurance undertaking from

activities which are beyond the scope of the implementation of the public health insurance

The insurance company performs in accordance with the laws and statutes of the insurance undertaking, and

funds under section 6 (1). 7.



9) § 13 para. 2 of Act No. 48/1997 Coll., as amended. ".



6. In article 7 (2). 4 the first sentence, the words "tangible and intangible

investment property ^ 10) "shall be replaced by the words" tangible and intangible

the property ".



Footnote 10) is repealed.



7. in article 7, paragraph 5 is added:



"(5) the financial resources of the insurance undertaking must be deposited in a bank enjoying

the advantages of the single licence according to the law of the European communities. '.



Footnote 4) is repealed.



8. In section 8 paragraph 1. 1 the words "measures published in the statute book"

shall be replaced by "implementing regulation".



9. section 12 reads as follows:



"section 12



(1) the organisational structure of the insurance undertaking consists of Headquarters, regional offices

(usually, one regional branch for higher territorial self-governing unit) and

other territorial departments. The regional offices and regional sites are

departments of the insurance undertaking, acting and pursue activities

on behalf of the insurance company.



(2) the headquarters of the Organization, as well as indicate the Organization, location, territorial

the scope and tasks of regional branches and local departments shall adjust the

the organizational order of the insurance company. ".



10. section 13 including the title reads as follows:



"section 13



The headquarters of the



(1) the headquarters of the activities of the organizational units of the insurance undertaking.



(2) the Headquarters carries out the decisions of the Board, decides on the activities of the

Insurance companies, secures interoperability with public authorities, other bodies

public administration, legal and natural persons and other activities

related to the implementation of public health insurance. ".



11. section 14 including the title reads as follows:



"section 14



The directors of the



(1) the statutory body of the insurance undertaking of the insurance undertaking which is a Director on the

the proposal of the Management Board of the insurance undertaking shall be elected and on a proposal from the Management Board of the insurance undertaking

recalled by the Chamber of deputies of Parliament.



(2) at the head of the regional branch Director, which appoints and dismisses the

the Director of the insurance company. ".



12. sections 15 and 16, including the headings are deleted.



13. the title of part four: "the authorities of the insurance company".



14. section 17 reads:



"§ 17



(1) the authorities of insurance companies are the Management Board and the Supervisory Board.



(2) an insurance undertaking is provided via the authorities of the participation of insured persons

Insurance companies, employers and insured persons of the State in the management of the insurance company. ".



15. in section 18 para. 1, 2 and 4, the words "or authority of the District insurance company"

shall be deleted.



16. in section 18 para. 2, the words "or County insurance ' shall be deleted.



17. in paragraph 3 of section 18 reads as follows:



"(3) a Board Member may not be simultaneously a member of the Supervisory Board and the

on the contrary. Member of the Board of directors cannot be a member of the Supervisory Board or in

a four-year term, following the end of its membership in the

The Governing Board; This is true even for the Supervisory Board in the case of its membership

on the Board. ".



18. in section 18 paragraph 5 and 6 are added:



"(5) The Insurance Authority may exercise the same function again

no more than 2 consecutive terms.



(6) The Insurance Authority shall not exercise his functions in employment

relation to the insurance company. The authority of the insurance undertaking shall be entitled to reimbursement of expenses

related to the performance of functions and the functions it can provide a reward

the amount laid down in the health insurance plan. ".



19. in section 18 para. 7, the words "and the district authorities of the insurance undertakings ' shall be deleted.



20. section 19, including the title.



21. In the heading of paragraph 20, the words "the central insurance companies" are deleted.



22. in § 20 paragraph 1 reads:



"(1) the Management Board shall decide on the



and approval of the regulations of the insurance undertaking),



(b) a disability insurance plan approval), accounts and annual

the message,



(c) the volume of payment) the approval of the medical establishment,



(d)) the value of point,



(e) the approval of the contracting policy),



(f) request the loan Insurance),



g) purchase of real estate,



h) purchase of tangible fixed assets at acquisition cost higher than 1

0000 0000 CZK



I the undersigned,)



j) using resources of the reserve fund,



to) other important matters related to the activities of the insurance undertaking, and

that jurisdiction's reserves. ".



23. in section 20 (2). 2, after the word "insured" is inserted after the word "Insurance".



24. in section 20, at the end of paragraph 2, the following sentences shall be added: "when the Submit

all present representatives of the State, all present the representatives of insured persons

or all present employers ' representatives of insured persons when dealing

The Board claimed that the proposed decision of the Administrative Board may jeopardise the

the financial balance of the public health insurance system or

balanced management of the insurance undertaking, the Governing Board does not accept the decision and

set a time limit which shall not be longer than 3 months, for the submission of

additional documents that confirm or refute this claim.

No later than 30 days from the expiry of the period laid down for the submission of

additional documents the Administrative Board will discuss the proposed decision again; to

the adoption of such a decision requires the consent of at least two-thirds of all

members of the Board. The hearing of objections must not endanger the fulfilment of the statutory

liabilities of the insurance undertaking. ".



25. In section 20 (2). 6, after the word "insured" is inserted after the word "Insurance" and

After the word "elect" the words "and refers to the public".



26. in § 20 paragraph 7 is added:




"(7) a representative of the employers insured persons to the Board of Directors shall appoint and

refer employers ' organisation. ".



27. In the heading of paragraph 21, the word "Insurance" is deleted.



28. in section 21 para. 1 the first sentence, the word "Insurance" shall be deleted and in the sentence

Second, the words "authorities of the insurance company" is replaced by "Governing Board".



29. in paragraph 21 of the paragraphs 2 and 3 shall be added:



"(2) the Supervisory Board shall examine the draft health insurance plan, accounting

statements and the draft of the annual report and shall submit its opinion to the joint

meetings of the Board and of the Supervisory Board.



(3) the Supervisory Board consists of



and three representatives of the State), one of which appointed and recalled by the Ministry of

Finance, Ministry of labour and Social Affairs and the Ministry of

health care,



(b) three representatives of the insured) the insurance company elected and odvolávaní by the

the Chamber of deputies of the Parliament,



c) 3 employers ' representatives of insured persons appointed and odvolávaní

employers ' organisations,



(d) one representative of the insured) the insurance company for each regional branch

elected Regional Assembly and odvolávaném and



(e) one representative of the employers) of insured persons for each county

Branch elected and odvolávaném employers ' organisations ".



30. in article 21, paragraphs 4 to 6 shall be deleted.



31. section 22, including the title reads as follows:



"§ 22



Joint meeting of the Management Board and the Supervisory Board



(1) joint meeting of the Management Board and the Supervisory Board shall be convened for the purpose of

review of the draft health insurance plan, financial statements and the proposal

the annual report of the insurance undertaking. A joint meeting is composed of all the members of the

The Management Board, the members of the Supervisory Board and the Director of the insurance company.



(2) the joint meeting of the Management Board and the Supervisory Board shall be convened by the Director

Insurance companies in sufficient time before the submission of health insurance

the plan, financial statements and draft annual report to the authorities of the insurance company. ".



32. section 23, including the title.



33. In article 24, paragraph 1 reads:



"(1) an insurance undertaking manages, develops and updates the information system

The insurance company. ".



34. In section 24a of para. 1 the first sentence, the words "or the district insurance company"

deleted and the second sentence, the words "or County insurance ' shall be deleted.



35. In section 24 c, the words "the district insurance company" shall be replaced by "regional

branch or the relevant territorial departments "and the words" shall ",

shall be replaced by "shall".



Article II



Transitional provisions



1. the Supervisory Board shall be accompanied by a representative of the insured persons and

employers insured persons for each of the regional offices within 6 months

from the effective date of this Act; for a period of 6 months from the effective date

This law fulfils the function of the supervisory board the Supervisory Board members only

Insurance election and appointed in accordance with the existing regulations.



2. an undertaking is required to include your organization in accordance with the

Act No. 553/1991 Coll., on the Czech General health insurance company

Republic, as amended by this Act, within 6 months from the date of entry into force of

of this Act.



3. the financial resources of the reserve fund in excess of at the date of acquisition

the effectiveness of this Act, the amount of the reserve fund as provided for by law No.

551/1991 Coll., on General health insurance company in the Czech Republic

the text of this law, the undertaking is required to convert to the underlying fund

within 15 days from the date of entry into force of this Act.



PART TWO



Amendment of the Act on departmental, industry, corporate, and other health

the insurance companies



Article. (III)



Act No. 280/1992 Coll., on departmental, industry, corporate, and other

health insurance undertakings, as amended by Act No. 10/1993 Coll., Act No.

15/1993 Coll., Act No. 60/1995 Coll., Act No. 145/1996 Coll., Act No.

48/1997 Coll., Act No. 93/1998 Coll., Act No. 125/1998 Coll., Act No.

225/1999 Coll., Act No. 220/2000 Coll., Act No. 48/2002 Coll. and Act No.

420/2003, is amended as follows:



1. In article 7 (2). 1 the first sentence with the number "30" is replaced by "60".



2. In article 7 (2). 1 third sentence, the words "to those published in the collection of

laws "shall be replaced by" implementing regulation ".



3. In section 10, paragraph 1 reads:



"(1) the authorities of employee insurance companies are the Management Board and the Supervisory Board.

The Administrative Board shall decide on the employment insurance



and approval of the disability insurance plan), accounts and annual

the message,



(b) the volume of payment) the approval of the medical establishment,



(c)) the value of point,



(d) the approval of the contracting policy),



(e) employee insurance) claims for credit,



f) purchase of real estate,



g) purchase of tangible fixed assets at acquisition cost higher than 1

0000 0000 CZK



h) seize the undersigned,



I) using resources of the reserve fund,



j) other important matters related to the activities of the employee

insurance and that jurisdiction's reserves. ".



4. In section 10, paragraph 1, the following paragraph 2 is added:



"(2) the insured person, the insured persons, employers and the State are represented in the

employee insurance institutions, each one-third. Lift up the

all present representatives of the State, all present the representatives of insured persons

or all present employers ' representatives of insured persons when dealing

The Board claimed that the proposed decision of the Administrative Board may jeopardise the

the financial balance of the public health insurance system or

balanced management of employee insurance companies, the Administrative Board decision

does not accept, and shall specify the period, which shall not be longer than 3 months, for

presentation of supporting documents, which confirm this claim, or

rebuts. No later than 30 days from the expiry of the period laid down for the

presentation of supporting documents the Administrative Board will discuss the proposed

the decision again; to adopt such a decision requires the consent of

at least two-thirds of all the members of the Management Board. The hearing of objections

must not jeopardise the fulfilment of legal obligations employee health

the insurance company. ".



Paragraphs 2 to 4 shall become paragraphs 3 to 5.



5. in article 15, paragraphs 2 and 3 shall be added:



"(2) an insurance undertaking is required to an employee following the terms

the Ministry of finance laid down for the submission of draft State

the budget and the State final account to submit this to the Ministry of

through the Ministry of health health insurance proposal

the plan for the following calendar year, the financial statements and the annual report for

last calendar year, and the auditor's report. ^ 12)



(3) the proposal for a health insurance plan, financial statements and the annual report

for the past year in accordance with paragraph 2, approved the Government's Chamber

the Chamber of deputies of the Parliament following the terms of discussion of the proposal

the State budget and State accounts. Approved by the annual

the report of an employee and the insurance company shall publish in an appropriate way. ".



6. in article 15, paragraph 3, the following paragraph 4 is added:



"(4) if the health insurance plan for employee insurance

approved before 1. before 1 January of the calendar year, the activity

employee insurance to approve health insurance plan

provizoriem laid down by the Ministry of finance. The basis for the determination of the

provisional draft disability insurance plan is on the calendar

year. ".



The current paragraph 4 shall become paragraph 5.



7. in article 16 paragraph 1. 4 (b)) including footnote # 17):



"(b)) the Fund for prevention. From the pool you can pay health care prevention beyond the

health care paid for by public health insurance according to the

a special legal regulation, ^ 17) in which it is demonstrated the preventive,

diagnostic or therapeutic effect and which is provided to the insureds in the

connection with their existing or impending disease. Resources

prevention can be used to fund the implementation of preventive health care

programs used for the detection of serious illness, support

rehabilitation recovery activities leading to a demonstrable improvement

the State of health of the participants and to support projects that support

increase the quality of health care, the healthy way of life and health

policy holders. The source of the Fund are funds from the share of positive

profit after tax fixed by the governing body

employee of an insurance undertaking of activities beyond the scope of the implementation of the

public health insurance as an employee and the insurance company performs in

accordance with the laws and statutes of the employee insurance and revenue under section

19 para. 1,



17) § 13 para. 2 of Act No. 48/1997 Coll., as amended. ".



8. in section 17 paragraph 1 reads:



"(1) the health insurance fund is used to pay for health care

paid for by public health insurance, allocations to the operating

Fund to cover the costs of the activities of the employee insurance, allocations

other funds and other payments to the extent laid down in the implementing

legal regulation. The source of the underlying fund are insurance payments to the

health insurance premiums and other receipts to the extent

the implementing regulation. ".



9. in section 18 para. 1 the first sentence, the words "minimum amount" shall be replaced by

"Above" and "3%" shall be replaced by the words "1.5%".



10. In section 19 (1):



"(1) the financial resources generated by the use of the basic Fund

employee insurance and revenue from fines, surcharges to


premiums and penalties charged by the insurance company in the field of public

health insurance insurance company can use as a source of employment

Fund prevention only in the case where he has filled the Reserve Fund and operate

balanced. ".



11. in paragraph 2 of section 19 reads as follows:



"(2) the financial resources of the occupational insurance companies must be stored in the

the Bank enjoying the advantages of the single licence pursuant to the law of the European

community. ".



Article IV



Transitional provision



The funds Reserve Fund pursuant to section 18 of Act No. 280/1992 Coll.,

about departmental, industry, corporate, and other health

insurance undertakings, as amended by law No 60/1995 Coll. and Act No. 149/1996 Coll.,

that extend beyond the effective date of this Act, the amount of the reserve

the Fund provided for by this Act, the employment insurance office to convert

the basic Fund within 15 days from the date of entry into force of this Act.



PART THREE



Amendment of the Act on general health insurance



Article. In



Act No. 592/1992 Coll., on premiums for general health insurance, in

amended by Act No. 10/1993 Coll., Act No. 15/1993 Coll., Act No. 166/1993

Coll., Act No. 333/1993 Coll., Act No. 42/1994 Coll., Act No. 241/1994

Coll., Act No. 58/1995 Coll., Act No. 145/1996 Coll., Act No. 48/1997

Coll., Act No. 125/1998 Coll., Act No. 29/2000 Coll., Act No. 118/2000

Coll., Act No. 258/2000 Coll., Act No. 492/2000 Coll., Act No. 137/2001

Coll., Act No. 48/2002 Coll., Act No. 176/2002 Coll., Act No. 309/2002

Coll., Act No. 424/2003 Coll., Act No. 437/2003 Coll., Act No. 461/2003

Coll. and Act No. 53/2004 is amended as follows:



1. In article 3, paragraph 3. 5 (b). (b)), the words "or 8" shall be deleted.



2. in article 3, paragraph 7 shall be deleted.



Paragraphs 8 to 14 shall become paragraphs 7 to 13.



3. In article 3, paragraph 3. 7, the following point (e)), which read as follows:



"e) for which the State pays the premiums (section 3 c).



4. In article 3, paragraph 3. 8 (a). (c)), the words "in paragraph 8" are replaced by the words "in

paragraph 7 ".



5. In section 3, paragraph 3. 10, the words "paragraphs 1 to 9 shall be replaced by" paragraph

1 to 8 ".



6. In section 3a, paragraph 3 shall be deleted.



Paragraphs 4 and 5 shall become paragraphs 3 and 4.



7. In § 3a paragraph 2. 3 in the introductory part of the sentence, the word "further" repealed, and in

subparagraph (a)), the words "§ 3 (1). 8 "are replaced by the words" § 3 (1). 7. "



8. In § 3a paragraph 2. 3, the following point (c)), which read as follows:



"(c)) for which the State pays the premiums (section 3 c).



9. In § 3a paragraph 2. 4 (b). (c)), the words "or 4" are deleted.



10. In article 13, the second sentence shall be deleted.



11. in section 20 (2). 1 the second sentence, the words "multiplied by a factor of age

the structure of the insured persons "shall be replaced by the words", their age structure,

gender and age groups of insured persons the cost indexes of public

health insurance ".



12. In article 20, paragraph 1, the following new paragraphs 2 and 3 shall be added:



"(2) the redistribution of the insurance cost indexes shall apply 18 age

groups of insured persons for each sex in the range from birth to 5 years, from

5 to 10 years and every 5 years to age groups from 80 to 85

years and groups from 85 years of age. Table age groups and their definition

are annexed to this Act.



(3) the cost indices are calculated as the share of the average cost of

insured person in that group by age and sex, and the average cost of

standard of the insured person. The average cost per client in the

Group by age and gender provides for the administrator account as the average cost

all health insurance companies on all insured persons in that group by

age and gender. The average cost of a standardised the insured person

provides for the administrator account as the average cost of all health insurance companies

women aged 15-20 years. To determine the cost indexes of a sentence

the first, and the average cost of the second sentence and the third sentence shall apply

data from the last financial year for which closed the calendar year. To do this, they are

all the health insurance companies are obliged to in the time limit laid down for the

submission of the annual reports of health insurance companies to disclose the account manager

the number of insured persons in each of the age categories by gender and

the total cost of the insured in the following categories. ".



Paragraphs 2 to 4 shall become paragraphs 4 to 6.



13. in § 20 paragraph 6 is added:



"(6) the rules on the management of the special account, including additional

correction, the details for a claim under section 21a, the calculation methodology

average costs referred to in paragraph 3, cost index age groups

including valuation and assigning costs to these groups, and the average

the cost of one of the insured person under section 21a, para. 2, the rules of procedure

the supervisory authority and the cost indexes for the calendar year

The Ministry of health, in agreement with the Ministry of finance

by Decree. "



14. in article 21, paragraph 1, including footnote No. 37):



"(1) The health insurance fund shall communicate to the eighth day of the calendar

Account Manager, their month of insured persons in each group

According to the age and sex of the insured to the first day of the month in these

insurance companies, their insured persons broken down according to a special legal

Regulation 37) for that ^ ^ is from the first day of this month the payer

the insurance law, and the number of those insured, applicable to the first day of the month

prior to 3 months the reallocation. The relevant health

insurance companies also communicate to 22. day of each month, account manager of

premiums in the period from 18. the day of the preceding month to 17.

day of the month.



37) Act No. 48/1997 Coll., as amended. ".



15. in section 21 para. 2 the words "the sum of shares per each

of the insured person which is liable for the State, and such

insured persons under the age of 60 years, found a share and from 60 years three

shares "shall be replaced by" share of the insured person in accordance with the standardised

paragraph 3, multiplied by the number of insured persons of the relevant standard

health insurance companies. The number of insured persons of the relevant standard

health insurance companies is calculated as the sum of the number of insured persons in each

Group by age and gender multiplied by the relevant cost index

This group ".



16. in article 21, paragraph 3, including footnote # 40):



"(3) the insured person's share of the standard shall be determined by the sum of the

all health insurance premiums, the total payment

the State for the insured, for which he is liable, penalties, fines, and other transactions

that are based on this Act or on the basis of specific legal

^ Law 40) income of the special account, and the interest incurred on the Special

account, minus fees for accounting operations and under the guidance of the special account,

divided by the total number of standard policyholders of all health

insurance companies.



40) for example, § 45 of Act No. 48/1997 Coll., section 6a of paragraph 1. 5 and § 23a para. 3

Act No. 280/1992 Coll., article. (IV) Law No. 60/1995 Coll., amending and

supplementing Act No. 553/1991 Coll., on the Czech General health insurance company

Republic, as subsequently amended, Act No. 280/1992 Coll., on

as amended, Act No. 20/1966 Coll., on the health care of the people,

in the wording of later regulations, and Act No. 182/1991 Coll., on the

insurance, as amended. ".



17. in section 21 para. 4, the first sentence is replaced by the sentence:

"If the selected health insurance company insurance

the total amount attributable to it under paragraph 2, does this

the insurance company the excess funds to the special account, within 3

working days from the day on which it was notified to the appropriate account manager

the total amount of. ".



18. in section 21 para. 5, the first sentence is replaced by the sentence:

"Where the amount of the insurance selected relevant health insurance

the total amount attributable to it under paragraph 2, account manager

pointing out the lack of health insurance funds, and

within 10 working days from the day on which it was notified to the account manager

the relevant total amount of. ".



19. in section 21 para. 5 at the end of the following sentence is added: "in a sentence

the second reason is not followed, if the failure to meet the obligations of the administrator account

is a failure to fulfil obligations referred to in paragraph 4, any medical

the insurance company. ".



20. in article 21, the following new section 21a, which including the footnotes No.

40A and 40b)) reads:



"§ 21a



(1) a special account under section 20 is used in addition to the redistribution of premiums and

other income of the special account pursuant to the occurrence of the insured in respect of

the relevant health insurance companies paid a particularly costly health

care (hereinafter referred to as "expensive care").



(2) the Cost of care means health care was paid to public health

insurance provided on the territory of the Czech Republic to the insured by

a special legal regulation, ^ 40a) in which the level of remuneration appropriate

health insurance for one insured person exceeded the period of one

the calendar year an amount corresponding to the victim's average cost

on one of the insured in the public health insurance system for the

the last financial year for which closed the calendar year (hereinafter referred to as "costly

the insured person ").




(3) the health insurance fund shall be entitled to reimbursement of 80% of the amount

that costly care exceeds the amount referred to in paragraph 2, if the administrators

account, as appropriate and properly showing cases of expensive care.



(4) the payment of expensive care is carried out in the form of monthly advance payments

and the annual accounts after the end of the relevant calendar year.



(5) the total volume of funds at the monthly advance payments

health insurance is determined by the percentage of the financial

the funds that are the subject of redistribution in a given month. This

share corresponds to the proportion of funds paid from the Special

in the last financial year for which the restricted account per calendar year for costly care of

funds that have been this year subject to reallocation.



(6) the amount of the advance payment is determined by individual health insurance

the percentage share of the total volume of funds on a monthly

advance payment corresponding to their share of the payment of expensive care in the

the last closed accounting year.



(7) an account administrator shall notify the competent health insurance company to 28. of the day

calendar month, the amount of the prepayment attributable to it. If the applicable

health insurance required pursuant to § 21 para. 4 take the extra

the financial resources of the special account and shall be entitled to an advance

payment to cover the costly care, give the administrator account netting

These claims and the resulting amount shall communicate to the competent health

insurance undertaking to 28. day of the calendar month.



(8) if the premium selected the relevant health insurance

the total amount to which he is entitled from both redistribution, does this

the insurance company the excess funds to the special account up to 3

working days from the date of referral to the resulting amount account manager

announced.



(9) where the amount of the insurance selected relevant health insurance

the total amount to which he is entitled from both redistribution, refer

the account manager of the insurance undertaking of the missing funds to the 10

working days from the date of referral to the resulting amount account manager

announced.



(10) the competent health insurance company be charged account manager within 3 months

After the accounting closing the calendar year all your costly insured

This year, the total remuneration for each of the insured person and the claimed

the amount referred to in paragraph 3.



(11) To check the validity and the accuracy of the billing of costly care

involved in all the health insurance companies. Account Manager checks the

through a joint inspection group composed of audit doctors

all health insurance companies. For the purposes of this Act are the revision

doctors delegated individual health insurance companies to control

the Group shall be entitled to inspect the Bill submitted by the costly care

any health insurance. The account administrator is entitled to require from

health insurance companies for additional documents necessary to verify the accuracy of the

communicated by the data. In cases where you cannot verify the accuracy of the data without

synergy medical devices that costly care

provided, the account administrator is entitled to require from them the necessary documents and

medical facilities are required to provide account administrators.



(12) the health insurance fund is required to communicate to the account manager

without delay, the cases in which on the basis of reduced medical

equipment reimbursement for expensive care and the amount of this reduction. In cases where the

health insurance fund has the right to compensation under a special

legislation, ^ 40b) is entitled to make a claim pursuant to paragraph 3 to

After you resolve the compensation for damage, and only for costs that were not covered

damages.



(13) an account administrator shall be calculated within 3 months from the receipt of the expense report total

the amounts to which they are entitled according to individual health insurance

paragraph 3, and compares them with the total amount of them provided by the monthly

advance payments. If it detects a difference between the administrator account and the amount of claims

advance payments greater than 0.01%, tackles this difference within the

the set-off referred to in paragraph 7 in the following month, but within

November of the year concerned.



40A), section 2, of Act No. 48/1997 Coll., as amended.



40B) section 55 of Act No. 48/1997 Coll., as amended by Act No. 258/2000 Coll. ".



21. the following annex is added:



"Appendix to Act No. 586/1992 Coll.



Age groups of insured persons for the redistribution of the insurance

Age: from to

---------------------------------

0 5

5 10

10 15

15 20

20 25

25 30

30 35

35 40

40 45

45 50

50 55

55 60

60 65

65 70

70 75

75 80

80 85

85 and more.



For the purposes of reallocation under this Act make up the age groups 0-5

years insured male, or female, from birth to

completion of the fifth year of life, IE. 364 days in a leap year 365 days

the date of the fourth birthday.



Groups of 5-10 years form the insured person from the first day of the sixth year of life,

i.e.. from the date of the completion of the fifth birthday of the tenth year of life.



Other age groups shall be defined accordingly. ".



Čl.VI



Transitional provisions



1. In the determination of average costs under section 20 (2). 3 of Act No.

593/1992 Coll., on premiums for general health insurance, as amended by

amended, as amended by this Act, (hereinafter referred to as the "Act"), shall be deducted

health insurance companies from the total cost of their client in the

age groups, costs paid pursuant to section 21a of the law. Similarly,

progresses in general health insurance company of the United States, which

a special account managed by the general health insurance scheme (hereinafter referred to as

"special account") under section 20 of the Act (hereinafter referred to as "account manager")

determination of the standard of the insured person pursuant to § 21 para. 3

the law.



2. In the determination of the average cost for the years 2005 and 2006 under section 20

paragraph. 3 of the Act shall be deducted from the total cost of health insurance on the

their insured persons in the relevant age groups, the amounts that would have been

paid as a costly care for insured persons in these age groups

pursuant to section 21a of the law in the years 2003 and 2004, if it was in these years §

21A of the law effective. Similarly, advances in the determination of the administrator account

on the standardized the insured person pursuant to § 21 para. 3 of the Act. When

determination of the total volume of financial resources on a monthly advance

the payment of health insurance pursuant to section 21a, para. 5 of the Act and the above

individual health insurance advance payments under section 21a, para.

6 of the Act in 2005 and 2006, the account administrator shall proceed as if the

This law was no longer effective in the years 2003 and 2004.



3. in 2005, the account administrator calculates the total amount

competent health insurance company from redistribution as the sum of



and 35%) amount calculated under section 20 (2). 2 and 3, § 21, art. 1 to 3 and §

21A, para. 3 to 6 and 13 of the Act, and



(b) 65% of the amount) calculated in accordance with point 5.



4. cancelled



5. The amount for the purposes of paragraph 3 (b). (b)) make up the sum of shares allotted

for each insured person competent health insurance company, which is from

the first day of the month of the premium payer State, subject to the

such insured person aged under 60 years of age found one portion and over 60

the age of three. One share is calculated from the sum of 60% of premiums

selected all health insurance companies in the period from 18. of the day

the previous month to 17. day of the month, total payments

the State for a person, for which he is liable, penalties, fines, and other transactions

that are based on law or on the basis of specific legal

the laws of the ^ 1) income of the special account, and the interest incurred on the Special

account reduced by charges for accounting operations and management of the special account

so that this total divided by the total number of insured persons, which is

the payer of the insurance State, with each such insured person above 60 years of age

age counts three times. The number of insured persons, which is from the first day

the applicable month by the payer of insurance State, broken down by the insured person to

60 years of age and over 60 years of age report a health insurance administrators

the account together with other data according to § 21 para. 1 of the law.



PART FOUR



Article. (VII)



Amendment of the Act on public health insurance



Act No. 48/1997 Coll., on public health insurance and amending and

certain related laws, as amended by Act No. 242/1997

Coll., Act No. 2/1998 Coll., Act No. 125/1998 Coll., Act No. 225/1999

Coll., Act No. 363/1999 Coll., Act No. 18/2000 Coll., Act No. 132/2000

Coll., Act No. 155/2000 Coll., the Constitutional Court declared under no.

167/2000 Coll., Act No. 220/2000 Coll., Act No. 258/2000 Coll., Act No.

458/2000 Coll., Act No. 176/2002 Coll., Act No. 198/2002 Coll., Act No.

285/2002 Coll., Act No. 309/2002 Coll., Act No. 320/2002 Coll., Act No.

222/2003 Coll., Act No. 274/2003 Coll., Act No. 361/2003 Coll., Act No.

424/2003 Coll., Act No. 422/2003 Coll., Act No. 461/2003 Coll., Act No.


85/2004 Coll. and Act No 359/2004 is amended as follows:



1. in article 15, paragraph 4, the following paragraphs 5 to 10, including

footnotes # 23 c) to 23e) are added:



"(5) from health insurance are reimbursed when providing health care

medicines and foods for special medical purposes, containing

the active substance of groups of active substances referred to in annex No. 2, if

holder of the marketing authorisation of the medicinal product, ^ 23 c), or in the case of

foods for special medical purposes, its manufacturer or distributor

(hereinafter referred to as "the applicant"), will ask the Ministry of health for their

inclusion in the list of medicinal products and foodstuffs for special medical

purposes covered by health insurance (hereinafter referred to as "the list"). ^ 23d)

each group of the active substances listed in annex No. 2 of the health

insurance always fully paid at least one medicinal product or foodstuff

for special medical purposes. Additionally, from health insurance shall be borne by

individually prepared medicinal products, radiopharmaceuticals and blood transfusion

preparations; the amount of reimbursement from health insurance provides

the implementing legislation.



(6) the list referred to in paragraph 5 leads the Ministry of health. The request for

inclusion in the List shall contain the



and) identification of the applicant,



(b) proof of valid registration) of the medicinal product, including its

attachments, ^ 23 c), or in the case of foods for special medical purposes, pattern

the label used for labelling foods for special medical

purposes. ^ 23e)



To a list you cannot write a medicine or food for special

medical purposes, if they do not contain any of the substances of the groups

the active substances listed in annex No. 2.



(7) for inclusion in the List shall inform the Ministry of health of the applicant

within 90 days of receipt of his application. The Ministry of health may, at the

examination of an application for inclusion in the list in the event of the detection of deficiencies

request the applicant to supplement the particulars referred to in paragraph 6 within 30 days.

If within this period the Ministry of health does not receive the supplement

the required information, the registration does not.



(8) on the disposal of the medicinal product or foods for special medical

the purpose of the list, the Ministry of health will decide if



and) has expired registration of the medicinal product in accordance with the Special

legislation, ^ 23 c)



(b)) the active substance that medicinal product or foodstuff for special

medical purposes includes, not listed in annex No. 2, or



(c)), the applicant shall request the delisting.



The decision to dispose of the medicine or foods for special

medical purposes from a list of the administrative code shall apply. ^ 47)



(9) the Ministry of Health publishes an updated list on your

page on the Internet.



(10) the Ministry of health shall lay down by Decree



a) medicines and foods for special medical purposes fully

paid for by health insurance,



(b) the amount of payment) the individual active substances belonging to groups

the active substances referred to in annex 2,



(c) the amount of the reimbursement) of foods for special medical purposes, containing the active

the substance of the groups of active substances referred to in annex 2,



(d) the amount of the reimbursement) individually prepared medicines,

radiopharmaceuticals and transfusion products from health insurance,



e) restrictions and conditions prescribing symbols

medicines and foods for special medical purposes covered by the

health insurance, including restrictions on the use of symbols and

medicines and foods for special medical purposes, when providing

health care in specialized sites.



23 c) Act No. 79/1997 Coll., on pharmaceuticals and on amendments and additions to some

related laws, as amended.



23d) Council Directive 89/105/EEC of 21 December 1988 December 1988 relating to the transparency

measures regulating the pricing of medicinal products used for human and

inclusion in the scope of national health insurance systems.



23e) section 15 of Decree No. 54/2004 Coll. on foodstuffs intended for particular

nutrition and how to use them. ".



Paragraphs 5 to 11 shall be renumbered as paragraphs 11 to 17.



2. in article 15, paragraphs 11 and 12 shall be deleted.



Paragraphs 13 to 17 shall be renumbered as paragraphs 11 to 15.



3. in article 15, paragraph 1 reads:



"(13) from health insurance fully paid by the in the provision of the constitutional

care medicines and foods for special medical purposes, registered in the

The list, individually prepared medicinal products, radiopharmaceuticals,

blood transfusion products and means of medical technology and the insured person shall

their pay is not taking part. ".



4. In § 53 para. the second and third sentence as follows: "health insurance company

determine payment amount. Credit assessment on the due premiums

enforceable regardless of legal power, if its delivery

15 days have elapsed. ".



5. In article 53 paragraph 1 the following new paragraphs 2 to 9, including the

footnote # 47a) are added:



"(2) the outstanding premiums and penalties may prescribe to the health insurance company

a statement of the arrears payment also. Statement of arrears must contain



the premium payer), which show arrears,



(b) the amount of the arrears by status) the payer's account of premiums on a specific day

based on the data reported by the payer or of the checks

carried out by the health insurance premiums of likely,

If it was fixed, and the finance charge calculated on that date,



(c)), the date on which the amount of the arrears was detected,



(d)), the competent health insurance account numbers, on which must be

arrears paid



e) instruction on the enforceability,



f) instruction on the objections,



(g)) the health insurance companies, which issued a statement of arrears, and

the date of issue. Statement of arrears shall be provided with an official stamp and

signed with the name, surname and the functions of an authorized person.



(3) a statement of arrears shall be enforceable on the day of its delivery. A statement of the

arrears shall be served on the same way as credit assessment.



(4) Against the statement of arrears can be health insurance company, which the statement

arrears has released, filed within 8 days from receipt of written comments, if

the payer does not agree with the existence of debt premiums on the insurance and finance charge memos

or its amount. The reason for the opposition is the payer of insurance shall in

objections noted.



(5) the health insurance fund on the basis of the objections within 30 days of their

delivery issues a decision, which the statement of arrears either confirm, if the

the amount of the arrears is fixed correctly, or cancelled. If health

the insurance company decides about the objections within the time limit referred to above, shall cease to be a statement of the

arrears of force.



(6) the health insurance fund may cancel the arrears on its own statement

initiative.



(7) The procedure for issuing the statement of arrears are not subject to the General provisions

on the administrative proceedings.



(8) the Enforceable decision on the matters referred to in paragraph 1 and

enforceable statements of arrears are heading for court ^ 47a) or

^ 47) administrative enforcement.



(9) the administrative execution of the decision on the matters referred to in paragraph 1 shall be

health insurance credit assessment issued at first instance

the proceedings; This applies to statements of arrears.



47A) Act No. 99/1963 Coll., the civil procedure code, as amended

regulations. ".



Paragraphs 2 to 5 shall be renumbered as paragraphs 10 to 13.



6. In paragraph 53, to the beginning of paragraph 10, the following sentence is added: "on the appeal

health insurance company against the decision referred to in paragraph 1 shall be decided by

the arbitration body health insurance. ".



7. Appendix 2 is added:



"Annex 2 to the Act No. 48/1997 Coll.



LIST OF GROUPS OF ACTIVE SUBSTANCES



------------------------------------------------------------------

The number of the name of a group of substances

Group

------------------------------------------------------------------

1 stomatologika

------------------------------------------------------------------

2 adsobční anatacida and protivředová of the drug from a group

H2-blockers, oral administration

------------------------------------------------------------------

3 protivředová of the drug from a group of Proton

pumps and other protivředová drugs

------------------------------------------------------------------

4 anti-spasmodics, oral administration

------------------------------------------------------------------

5 anti-spasmodics, other application path

------------------------------------------------------------------

6 anticholinergics and antispasmodics in combination

with analgesics

------------------------------------------------------------------

7, antiflatulencia agents, oral administration

------------------------------------------------------------------

8 agents, other application path

------------------------------------------------------------------

9 antiemetics, oral administration

------------------------------------------------------------------

10 antiemetics, other application path

------------------------------------------------------------------

11 hepatika and hepatoprotektiva and other drugs acting

the bile ducts, or liver

------------------------------------------------------------------


12 laxatives and other drugs for the cleansing of the bowel

------------------------------------------------------------------

13 antidiarhoika, anti-infective and anti-inflammatory drugs

the gastrointestinal tract, the oral administration of

------------------------------------------------------------------

14 antidiarhoika, anti-infective and anti-inflammatory drugs

the gastrointestinal tract, the other the application paths

------------------------------------------------------------------

15, including lowered enzyme preparation

------------------------------------------------------------------

16 short-acting insuliny

------------------------------------------------------------------

17 insuliny intermediate acting, including a combination of

------------------------------------------------------------------

18 insuliny long-acting

------------------------------------------------------------------

19 insulinů and analogues insuliny used for the application

using the insulin pump

------------------------------------------------------------------

20 oral antidiabetics of biguanides group

and glitazonů

------------------------------------------------------------------

21 oral agents from a group of sulphonylurea

and meglitinidů, or other antidiabetic drugs

------------------------------------------------------------------

22 vitamin A or D, including combinations, oral

Administration

------------------------------------------------------------------

23 vitamin A or D, including combinations thereof other

application path

------------------------------------------------------------------

24 calcium salts, oral administration

------------------------------------------------------------------

25 the combination of oral administration of calcium salts

------------------------------------------------------------------

26 salts of calcium, other application path

------------------------------------------------------------------

27, the oral administration of potassium salts

------------------------------------------------------------------

28 salts of potassium, other application path

------------------------------------------------------------------

29 salt of magnesium and other mineral products, oral

Administration

------------------------------------------------------------------

30 salt magnesium, the other the application paths

------------------------------------------------------------------

31 fluorine salts, oral administration

------------------------------------------------------------------

32 other drugs affecting digestive system

------------------------------------------------------------------

33 antithrombotika of vitamin K antagonist

------------------------------------------------------------------

34 antithrombotika of a group of heparin and antithrombinu III

------------------------------------------------------------------

35 antithrombotika of a group of low molecular weight heparins

------------------------------------------------------------------

36 antiplatelet drugs heparin

------------------------------------------------------------------

37 of fibrinolytic enzymes

------------------------------------------------------------------

38 antifibrinolytics, oral administration

------------------------------------------------------------------

39 antifibrinolytics, other application path

------------------------------------------------------------------

40 vitamin K and other hemostatics

------------------------------------------------------------------

41 the coagulation factors (coagulation factor VIII)

------------------------------------------------------------------

42 the coagulation factors (coagulation factor IX)

------------------------------------------------------------------

43 other clotting factors

------------------------------------------------------------------

44 iron salts, oral administration

------------------------------------------------------------------

45 iron salts in combination with folic acid and other

the combination of the

------------------------------------------------------------------

46 iron salts, other application path

------------------------------------------------------------------

47 vitamin B12, folic acid and other antianemika

------------------------------------------------------------------

48 erythropoietin and other drugs blood and hematopoietic

authorities

------------------------------------------------------------------

49 substituents plasma and plasma proteins (albumin)

------------------------------------------------------------------

50 plasma and plasma proteins, another (others)

------------------------------------------------------------------

51 total parenteral nutrition

------------------------------------------------------------------

52 by solutions has the solution

------------------------------------------------------------------

53 other by solutions for peritoneal dialysis

and to hemodialysis

------------------------------------------------------------------

54 additives for intravenozním solutions

------------------------------------------------------------------

55 other drugs used in diseases of the krvetvorného system

------------------------------------------------------------------

56 cardiac glycosides

------------------------------------------------------------------

57 class I and III antiarrhythmics, oral administration

------------------------------------------------------------------

58 antiarrhythmics, the other the application paths

------------------------------------------------------------------

59 adrenergic and dopaminergic agents and other cardiac preparations

------------------------------------------------------------------

60 vasodilator substance for heart disease, oral

Administration for chronic treatment

------------------------------------------------------------------

61 vasodilator substance for heart disease, oral

filing for emergency treatment

------------------------------------------------------------------

62 prostaglandins and other cardiac preparations

------------------------------------------------------------------

63 antihypertensives-antiadrenergic substances and substances

acting on the smooth muscle of arterioles, Inc. a combination of

with diuretics, oral administration

------------------------------------------------------------------

64 other antihypertensive drugs, the application path

------------------------------------------------------------------

65 diuretics lower diuretickým effect

------------------------------------------------------------------

66 high effect of diuretics, oral administration

------------------------------------------------------------------

67 diuretics with high effect, the other the application paths

------------------------------------------------------------------

potassium-sparing diuretics, 68

------------------------------------------------------------------

69 combination diuretic

------------------------------------------------------------------

70 peripheral vasodilators, oral administration

------------------------------------------------------------------

71 peripheral vasodilators and vasoprotektiva, other

application path

------------------------------------------------------------------

72 vazoprotektiva and venofarmaka

------------------------------------------------------------------

73 non-selective beta blockers, oral administration

------------------------------------------------------------------

74 selective beta blockers and a combination of alpha and beta

activities, oral administration

------------------------------------------------------------------

75 beta blockers, the other the application paths

------------------------------------------------------------------

76 the combination of beta blockers with other antihypertensive drugs

------------------------------------------------------------------

77 vápníkového channel blockers from the Group

dihydropyridinů, oral solution

------------------------------------------------------------------

78 calcium channel blockers of the other groups,

oral administration of

------------------------------------------------------------------

79 calcium channel blockers, the other the application paths

------------------------------------------------------------------

80 ACE inhibitors acting less than 24 hours

------------------------------------------------------------------

81 other ACE-inhibitors

------------------------------------------------------------------

82 combinations acting on the renin-angiotensin

system with other antihypertensive agents

------------------------------------------------------------------

83 medicines on the renin-angiotensin system

with the exception of the ACE-inhibitors

------------------------------------------------------------------

Statin lipid lowering medicines from a group of 84

------------------------------------------------------------------

lipid lowering medicines from a group of 85 Fibrates and other groups

------------------------------------------------------------------

86 the other drugs used in cardiovascular diseases

System

------------------------------------------------------------------

87 antifungals for topical use of a group of antibiotics,

imidazolových and triazolových derivatives


------------------------------------------------------------------

88 other antifungals for topical use

------------------------------------------------------------------

89 emolliencia and protectives

------------------------------------------------------------------

90 of the drug for the treatment of wounds and ulcers

------------------------------------------------------------------

91 antipsoriatics

------------------------------------------------------------------

92 antibiotics for external use

------------------------------------------------------------------

93 antibiotics and chemotherapeutics for external use

and antivirals

------------------------------------------------------------------

94 moderately effective and weak effective corticosteroids

for topical use and their combinations

------------------------------------------------------------------

95 very strong and potent corticosteroids to a local

Administration and their combinations

------------------------------------------------------------------

96 corticosteroids in combination with antibiotics or

antiseptics

------------------------------------------------------------------

97 corticosteroids in other combinations

------------------------------------------------------------------

98 antiseptics and desinficiencia

------------------------------------------------------------------

99 active substances against acne and other dermatological medicinal

the substance

------------------------------------------------------------------

100 other drugs used in diseases of the skin

------------------------------------------------------------------

101 gynecological chemotherapy agents and antifungal agents

for topical use

------------------------------------------------------------------

102 gynecological antiinfectives and antiseptics for local

the use of the

------------------------------------------------------------------

103 of the drug rising tone of the uterus

------------------------------------------------------------------

104 drug reduce the tone of the uterus

------------------------------------------------------------------

105 prolactin inhibitors

------------------------------------------------------------------

106 male sex hormones

------------------------------------------------------------------

107 female sex hormones estrogen from the group,

oral administration of

------------------------------------------------------------------

108 female sex hormones estrogen from the group,

the other path of the application

------------------------------------------------------------------

109 female hormones from a group of progestins

------------------------------------------------------------------

the combination of female reproductive hormones 110

------------------------------------------------------------------

111 gonadotropins and other ovulation stimulants

------------------------------------------------------------------

112 other sex hormones, androgens and modulators

hormones

------------------------------------------------------------------

113 other urologicals, including spasmolytik

------------------------------------------------------------------

114 drugs used in benign prostatic hyperplasii

and the other the gynecologist

------------------------------------------------------------------

115 other drugs used in diseases of the urogenital

System

------------------------------------------------------------------

front lobe of the pituitary hormones 116 and their analogues

------------------------------------------------------------------

the rear lobe of the pituitary gland 117 hormones and their analogues

------------------------------------------------------------------

118 the hypothalamus hormones and their analogues

------------------------------------------------------------------

119 total use of corticosteroids, oral administration

------------------------------------------------------------------

120 for the total use of corticosteroids, other paths

application

------------------------------------------------------------------

121 thyroid hormones and following therapy

------------------------------------------------------------------

122 of antithyroid drugs

------------------------------------------------------------------

123 glucagon and homeostatika calcium and other

hormonal drugs

------------------------------------------------------------------

124 other medicines from a group of hormones

------------------------------------------------------------------

antibiotics tetracycline and amfenikolová 125

------------------------------------------------------------------

126 Penicillins with a wide spectrum of oral administration

------------------------------------------------------------------

127 Penicillins with a wide spectrum of other application path

------------------------------------------------------------------

128 Penicillins sensitive to betalaktamáze, oral administration

------------------------------------------------------------------

129 Penicillins sensitive to betalaktamáze, other paths

application

------------------------------------------------------------------

130 betalaktamáze and resistant to Penicillins, combinations

Penicillins including betalactamases inhibitors,

oral administration of

------------------------------------------------------------------

131 different lactam antibiotics, oral administration

------------------------------------------------------------------

132 different lactam antibiotics, the other the application paths

------------------------------------------------------------------

133 sulfonamides and trimethoprim

------------------------------------------------------------------

134 macrolide antibiotics and their combinations

with antibacterial drugs

------------------------------------------------------------------

135 linkosamidová antibiotics

------------------------------------------------------------------

136 aminoglycoside antibiotics

------------------------------------------------------------------

137 quinolone chemotherapeutics

------------------------------------------------------------------

138 other antibiotics or chemotherapy, including

urinary chemotherapeutic agents

------------------------------------------------------------------

139 imidazolová chemotherapy for the total use of

and other antibacterial agents

------------------------------------------------------------------

140 antimycotics for systemic use

------------------------------------------------------------------

141 other antimycobacterial agents

------------------------------------------------------------------

142 systemic antivirals for the treatment of herpes,

cytomegalovirových infections and some other

viral infections

------------------------------------------------------------------

143 antiretroviral therapy

------------------------------------------------------------------

144 animal immunoglobulins against the stafylokokovým infections

------------------------------------------------------------------

145 animal immunoglobulins against diphtheria

------------------------------------------------------------------

146 animal immunoglobulins against snake venom

------------------------------------------------------------------

147 animal immunoglobulins against botulism

------------------------------------------------------------------

148 animal immunoglobulins against gas gangrene

------------------------------------------------------------------

149 animal immunoglobulins against rabies

------------------------------------------------------------------

150 immunoglobulins, normal human, for extravascular

application

------------------------------------------------------------------

151 immunoglobulins, normal human, intravascular

application

------------------------------------------------------------------

152 human tetanus immunoglobulin

------------------------------------------------------------------

153 human immunoglobulins against the hepatitis

------------------------------------------------------------------

154 human immunoglobulins against rabies

------------------------------------------------------------------

155 other human specific immunoglobulins

------------------------------------------------------------------

156 tetanus vaccine

------------------------------------------------------------------

157 other bacterial vaccines

------------------------------------------------------------------

158 of vaccine against tuberculosis

------------------------------------------------------------------

159 rabies vaccine

------------------------------------------------------------------

160 other vaccines and immunoglobulins and other

antiinfectives for systemic use

------------------------------------------------------------------

161 other medicines from a group of antibiotics, chemotherapeutic agents

immunoglobulins or vaccines

------------------------------------------------------------------

a group of alkylating antineoplastic agents from 162 substances,

oral administration of

------------------------------------------------------------------

alkylating antineoplastic agents from a group of 163 substances, other

application path

------------------------------------------------------------------


164-folic acid analogues antimetabolites,

oral administration of

------------------------------------------------------------------

165-folic acid analogues antimetabolites,

the other path of the application

------------------------------------------------------------------

166 antimetabolites-purine and pyrimidine analogues,

oral administration of

------------------------------------------------------------------

167 antimetabolites-purine analogues, the other the application paths

------------------------------------------------------------------

168 antimetabolites-pyrimidine analogues

------------------------------------------------------------------

169 of the vinca alkaloids and analogues

------------------------------------------------------------------

170 podofylotoxinu derivatives, oral administration

------------------------------------------------------------------

171 podofylotoxinu derivatives, the other the application paths

------------------------------------------------------------------

172 taxanes

------------------------------------------------------------------

173 anthracyclines and their derivatives

------------------------------------------------------------------

174 other cytotoxic antibiotics

------------------------------------------------------------------

175 Platinum antineoplastic agents

------------------------------------------------------------------

176 other antineoplastic agents, oral administration

------------------------------------------------------------------

177 other antineoplastic agents in addition to Platinum, the other

application path

------------------------------------------------------------------

178 with a cytostatic effect of endocrine

------------------------------------------------------------------

179 antagonists of hormones and related substances used

in Oncology

------------------------------------------------------------------

180 inhibitors of steroid hormones that are used in Oncology

------------------------------------------------------------------

181 immunostimulatory and immunomodulatory drugs including

the interferon

------------------------------------------------------------------

182 other immunostimulatory and immunomodulatory drugs

------------------------------------------------------------------

183 immunosuppressive drugs, oral administration

------------------------------------------------------------------

184 immunosuppressive drugs the other path of the application

and other antineoplastic agents

------------------------------------------------------------------

185 nonsteroidal anti-inflammatory drugs from the Group

butylpyrazolidinů acetic acid and derivatives,

oral administration of

------------------------------------------------------------------

186 nonsteroidal anti-inflammatory drugs from the Group derivatives

propionic acid and fenamátů, oral administration

------------------------------------------------------------------

187 other nonsteroidal anti-inflammatory drugs

for oral administration

------------------------------------------------------------------

188 nonsteroidal anti-inflammatory drugs from the Group derivatives

acetic acid, acid derivatives from the Group

propionic and fenamátů, the other the application paths

------------------------------------------------------------------

189 specific anti-inflammatory drugs and other medicine

When diseases of the musculoskeletal system

------------------------------------------------------------------

190 locally applied nonsteroidal anti-inflammatory drugs

------------------------------------------------------------------

191 muscle relaxants

------------------------------------------------------------------

192 anti-gout agents and other paid products group M

not included in the other groups

------------------------------------------------------------------

193 drug acting on bone mineralisation

------------------------------------------------------------------

194 other drugs used in diseases of the musculoskeletal

System

------------------------------------------------------------------

195 from a group of local anaesthetics of esters

------------------------------------------------------------------

196 local anesthetics of the amide hydrolysis group

------------------------------------------------------------------

197 local anesthetics of the amide hydrolysis in the combination group

with adrenaline or other a vasoconstrictor substance

------------------------------------------------------------------

198 analgesics-anodyna (opioids) from a group of derivatives

morphine, oral administration

------------------------------------------------------------------

199 analgesics-anodyna (opioids) from the Group analogues

morphine, oral administration

------------------------------------------------------------------

analgesic-anodyna 200 (opioids) from the Group analogues

morphine, the other the application paths

------------------------------------------------------------------

201 analgesics-antipyretics from the Group derivatives

Salicylic acid, oral administration

------------------------------------------------------------------

202 other analgesics-antipyretics, oral administration

------------------------------------------------------------------

203 antimigraine preparations

------------------------------------------------------------------

204 antiepileptics from a group of barbiturates

------------------------------------------------------------------

205 from the Group hydantoinátů, antiepileptic oxazolidinů

and sukcinimidů

------------------------------------------------------------------

206 antiepileptics from a group of benzodiazepines and karboxamidů

------------------------------------------------------------------

207 antiepileptics from the Group derivatives of fatty acids

------------------------------------------------------------------

208 other antiepileptics

------------------------------------------------------------------

209 anticholinergic antiparkinsonian

------------------------------------------------------------------

dopaminergic antiparkinsonian 210 from a group of levodopa

and their derivatives

------------------------------------------------------------------

211 antiparkinsonian from other groups

------------------------------------------------------------------

212 antiparkinsonian acting on MAO or COMT

------------------------------------------------------------------

213 antipsychotic drugs, Neuroleptics for oral administration,

Neuroleptics-phenothiazines, oral administration

------------------------------------------------------------------

214 Neuroleptics-butyrofenony and indole derivatives

oral administration of

------------------------------------------------------------------

215 Neuroleptics-thioxantheny, difenylbutylpiperidiny,

oral administration of

------------------------------------------------------------------

216 Neuroleptics-diazepiny, oxazepiny, thiazepiny,

benzamidy, oral solution

------------------------------------------------------------------

217 other antipsychotic drugs, oral administration

------------------------------------------------------------------

218 lithium

------------------------------------------------------------------

219 antipsychotic drugs, Neuroleptics other paths of the application-

nedepotní products

------------------------------------------------------------------

220 antipsychotic drugs, Neuroleptics other paths of the application-

depot preparations

------------------------------------------------------------------

221 anxiolytics, oral administration

------------------------------------------------------------------

222 anxiolytics and hypnotics, other application path

------------------------------------------------------------------

Antidepressants non-selectively inhibits reverse 223

the uptake of Monoamines, oral administration

------------------------------------------------------------------

224 antidepressants selectively inhibits reverse

the uptake of Monoamines, oral administration

------------------------------------------------------------------

225 antidepressants acting on possess monoamine oxidase inhibitory

and other antidepressants, oral administration

------------------------------------------------------------------

226 antidepressants, other application path

------------------------------------------------------------------

227 stimulants and nootropics and medicines intended for the treatment of

dementia

------------------------------------------------------------------

228 parasympatomimetika from a group of inhibitors

cholinesterase, oral administration

------------------------------------------------------------------

229 parasympatomimetika, the other the application paths

------------------------------------------------------------------

230 medicines in the treatment of Vertigo and other pharmaceuticals

used for the diseases of the nervous system

------------------------------------------------------------------

231 other drugs used in diseases of the Central

the nervous system

------------------------------------------------------------------

232 antimalarial drugs

------------------------------------------------------------------

233 anthelmintic and antiektoparazitika and other medicines

of a group of drugs used in parasitic diseases

------------------------------------------------------------------

234 nasal corticosteroids including hypoallergenic


------------------------------------------------------------------

235 inhaled sympathomimetics including combinations

------------------------------------------------------------------

236 and anticholinergics, inhaled corticosteroids

aerosol

------------------------------------------------------------------

237 and anticholinergics, inhaled corticosteroids

other pharmaceutical forms

------------------------------------------------------------------

238 other inhalant anti-asthmatics

------------------------------------------------------------------

239 anti-asthmatics, oral administration

------------------------------------------------------------------

240 anti-asthmatics, other application path

------------------------------------------------------------------

241 other anti-asthmatics, oral administration

------------------------------------------------------------------

242 other anti-asthmatics, other application path

------------------------------------------------------------------

In addition, 243 expectorants oral administration

------------------------------------------------------------------

244 in addition, expectorants other application path

------------------------------------------------------------------

245 antitussive opioid derivatives from the Group

------------------------------------------------------------------

246 other cough suppressant.

------------------------------------------------------------------

247 non-sedating antihistamines

------------------------------------------------------------------

248 sedating antihistamines for oral administration

------------------------------------------------------------------

249 antihistamines, other application path

------------------------------------------------------------------

250 other drugs used in diseases of the respiratory system

------------------------------------------------------------------

251 ophthalmologicals-antibiotics

------------------------------------------------------------------

252 ophthalmologicals-chemotherapy and antiseptics

------------------------------------------------------------------

253 ophthalmologicals-antivirals

------------------------------------------------------------------

our 254-corticosteroids

------------------------------------------------------------------

our 255-nonsteroidal anti-inflammatory drugs

------------------------------------------------------------------

our 256-a combination of anti-inflammatory drugs

with antiinfektivy

------------------------------------------------------------------

257 antiglaukomatika from a group of sympathomimetic agents

and parasympatomimetik

------------------------------------------------------------------

258 antiglaukomatika from the Group of beta blockers

------------------------------------------------------------------

259 other antiglaukomatika

------------------------------------------------------------------

260 mydriatika and cykloplegika

------------------------------------------------------------------

261 dekongescenty and antialergika

------------------------------------------------------------------

262 local anaesthetics and other ophthalmologicals

------------------------------------------------------------------

263 other drugs used in diseases of the sensory organs

------------------------------------------------------------------

264 therapeutic extracts standardized allergens

oral administration of

------------------------------------------------------------------

265 therapeutic non-standardised extracts of allergens

oral administration of

------------------------------------------------------------------

266 therapeutic extracts standardized allergens

the other path of the application

------------------------------------------------------------------

267 therapeutic non-standardised extracts of allergens

the other path of the application

------------------------------------------------------------------

268 basic antidotes and Phage lysates

------------------------------------------------------------------

269 antidotes used organophosphates poisoning

------------------------------------------------------------------

270 antidotes used in some heavy metals poisoning

------------------------------------------------------------------

271 antidotes used in cyanide poisoning

------------------------------------------------------------------

272 antidotes used in the treatment of chemotherapy, oral

Administration

------------------------------------------------------------------

273 antidotes used in the treatment of chemotherapy, other

application path

------------------------------------------------------------------

274 the secretion of pituitary gland hormones tests, diagnosis function

Kidney and thyroid function

------------------------------------------------------------------

275 a tuberculin test

------------------------------------------------------------------

276 tests for allergic diseases

------------------------------------------------------------------

277 other drugs for diagnostic and therapeutic purposes,

oral administration of

------------------------------------------------------------------

278 other drugs for diagnostic and therapeutic purposes,

the other path of the application

------------------------------------------------------------------

279 nutrition without phenylalanine and other amino acids,

the combination of amino acids/carbohydrates/minerals/vitamins

------------------------------------------------------------------

the combination of carbs/proteins 280/minerals/vitamins,

eventually. grease and other food combinations

------------------------------------------------------------------

281 amino acids including combinations with polypeptides

------------------------------------------------------------------

282 refunds milk

------------------------------------------------------------------

283 solvents and irrigation solutions and other medicines

from the Group várií

------------------------------------------------------------------

284 water-soluble nefrotropní hyperosmolar RTG

contrast agents

------------------------------------------------------------------

285 water-soluble nefrotropní nízkoosmolární RTG

contrast agents

------------------------------------------------------------------

286 water-soluble hepatotropní and vodonerozpustné RTG

contrast agents

------------------------------------------------------------------

287 radiopaque preparations containing barium sulfate

------------------------------------------------------------------

288 by contrast and contrast medium

for Ultrasound

------------------------------------------------------------------

289 individually prepared radiopharmaceutical for diagnosis

------------------------------------------------------------------

290 individually prepared radiopharmaceutical therapy

------------------------------------------------------------------

291 individually prepared medicines from a group

dermatologik (with the exception of the kosmetik)

------------------------------------------------------------------

292 individually prepared medicines from a group

ophthalmic and otologik

------------------------------------------------------------------

293 individually prepared medicines from a group

analgesics-anodyn (opioids)

------------------------------------------------------------------

294 individually prepared medicines from a group

gynekologik

------------------------------------------------------------------

295 individually prepared medicines from the pharmaceutical group

digestive system

------------------------------------------------------------------

296 individually prepared medicines from a group

otorhinolaryngologik and antiastmatik

------------------------------------------------------------------

297 of packed products

------------------------------------------------------------------

298 trombocytární preparations

------------------------------------------------------------------

299 preparations of plasma

------------------------------------------------------------------

300 leukocyte preparations "

------------------------------------------------------------------



Article. (VIII)



In the list of medicinal products, and foods for special medical purposes

under § 15 para. 5 the first sentence Act No. 48/1997 Coll., on public

health insurance and amending and supplementing certain related

laws, as amended by article. VII, point 1 to this Act, the date of application

the effectiveness of this law written to medicines and food for

Special medical purposes contained to this day in the General

health insurance companies in the Czech Republic. List of medicinal products and

foods for special medical purposes under the first sentence, the Ministry of

Health shall publish the effective date of this Act on its

page on the Internet.



PART FIVE



The EFFECTIVENESS of the



Article. (IX)



This Act shall take effect on the first day of the first month following

After the date of its publication, with the exception of article 11 to 21 and article VI,

that will become effective on 1 January 2004. January 1, 2005.



Fort Worth Star Telegram in r.



Klaus r.



Spidla in r.



1) for example, § 45 of Act No. 48/1997 Coll., on public health


insurance and amending and supplementing certain related laws, as amended by

amended, § 6a of paragraph 1. 5 and § 23a para. 3 of Act No. 280/1992

Coll., on departmental, industry, corporate, and other health

insurance companies, as amended.

Related Laws